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Objective:  Disease  progression  because  of  acquired  resistance  is common  in  advanced  or metastatic  epi-
dermal growth  factor  receptor  (EGFR)-mutation  positive  non-small  cell  lung  cancer  (NSCLC),  despite
initial  response  to  EGFR-tyrosine  kinase  inhibitors  (TKIs).  In Japan,  transbronchial  tissue  biopsy  is the
most  common  sampling  method  used  for re-biopsy  to  identify  patients  eligible  for  treatment.  We  aimed
to investigate  the  success  rate  of re-biopsy  and  re-biopsy  status  of  patients  with  advanced  or  metastatic
NSCLC  completing  ﬁrst-line  EGFR-TKI  therapy.
Patients and methods:  This  was  a retrospective,  multi-center,  Japanese  study.  The  target  patients  in  the
study  were  EGFR  mutation-positive  NSCLC  patients.  The  primary  endpoint  was  the  success rate  (number
of cases  in which  tumor  cells  were  detected/total  number  of re-biopsies  performed  × 100).  Secondary
endpoints  included  differences  between  the  status  of  the  ﬁrst  biopsy  and  that  of the  re-biopsy  in  the
same  patient  population,  and  the  details  of cases  in  which  re-biopsy  could  not be  carried  out.  Re-biopsy-
associated  complications  were  also  assessed.
Results:  Overall,  395  patients  were  evaluated  (median  age  63 years),  with  adenocarcinoma  being  the
most  common  tumor  type.  Re-biopsy  was  successful  in 314  patients  (79.5%).  Compared  with  the  sam-
pling  method  at ﬁrst  biopsy,  at re-biopsy,  the  surgical  resection  rate  increased  from  1.8% to 7.8%, and
percutaneous  tissue  biopsy  increased  from  7.6%  to 29.1%,  suggesting  the  difﬁculty  of  performing  re-
biopsy.  Approximately  half  of the  patients  had  T790M  mutations,  which  involved  a  Del19  mutation  in
55.6%  of  patients  and  an  L858R  mutation  in  43.0%.  Twenty-three  patients  (5.8%) had re-biopsy-  associated
complications,  most  commonly  pneumothorax.
Abbreviations: CT, computed tomography; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene
omolog; NSCLC, non-small cell lung cancer; RET, rearranged during transfection; PS, performance status; ROS1, c-ros oncogene 1; TKI, tyrosine kinase inhibitor.
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apan.
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Conclusions:  Success  rate for  re-biopsy  in this  study  was  approximately  80%.  Our  study  sheds  light  on  the
re-biopsy  status  after  disease  progression  in  patients  with  advanced  or metastatic  NSCLC.  This  information
is  important  to improve  the selection  of  patients  who  may  beneﬁt  from  third-generation  TKIs.
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. Introduction
Non-small cell lung cancer (NSCLC) accounts for around 85%
f all lung cancers. Appropriate therapy for unresectable cases is
etermined by means of a genetic test for mutations in tumor DNA
ncoding the tyrosine kinase domain of the epidermal growth fac-
or receptor (EGFR) gene [1].
EGFR-tyrosine kinase inhibitors (TKIs) are recommended as
rst-line therapy for patients with EGFR mutation-positive tumors,
eing associated with improved outcomes compared with doublet
hemotherapy [2,3]. Despite initial responses to EGFR-TKI treat-
ent, however, most patients with advanced or metastatic NSCLC
ill have disease progression within 1 to 2 years after treatment
nitiation because of acquired resistance [2,4–6].
In approximately 60% of patients, the mechanism of acquired
esistance is the development of an additional mutation, EGFR
790M [7,8]. Third-generation TKIs that target this mutation,
simertinib [AZD9291] has just been launched in Japan for the
reatment of patients with advanced NSCLC, and identifying T790M
utations is important for appropriate treatment with these new
KIs [9]. In such patients, re-biopsy could provide further informa-
ion, including the identiﬁcation of histological or genetic changes,
hich may  help identify patients eligible for treatment [10]. In
apan, transbronchial tissue biopsy is the most common sampling
ethod used for re-biopsy, however, several factors limit the suc-
ess rate of re-biopsy, such as difﬁculty accessing some tumor sites,
nvasive nature of sampling methods [11–13]. The success rate
f re-biopsy after EGFR-TKI or ALK-TKI failure has been reported
o be 73% to 95% in previous reports [11,12,14–19], but little is
nown about the national rate. Therefore, the present study aimed
o investigate the success rate of re-biopsy and the status of re-
iopsy among patients with advanced or metastatic NSCLC who
ave completed ﬁrst-line EGFR-TKI therapy in Japan.
. Patients and methods
.1. Study design
The study was a multicenter, observational, retrospective study
onducted in 28 centers in Japan.
.2. Patients
Patients had to fulﬁll all the following criteria to be included
n the study: age 20 years or over; histologically or cytologically
onﬁrmed EGFR mutation-positive NSCLC; progressive disease con-
rmed radiographically after EGFR-TKI treatment; and re-biopsy
erformed after 1 January 2013, except re-biopsy of the pleural
ffusion. The exclusion criteria were as follows: involvement in the
lanning and/or conduct of the present study or previous enrol-
ent in the present study.
.3. Ethical considerationsThe study was conducted according to the principles of the
eclaration of Helsinki and the “Ethical Guidelines for Medical
esearch Involving Human Subjects” (dated on December 22th,blished  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2014) in Japan. Ethical approval was granted by the institu-
tional/ethical review boards of each participating study center.
2.4. Study endpoints
The primary endpoint was the practical success rate deﬁned as
the number of patients in which tumor cells were detected/total
number of re-biopsies performed × 100. The secondary endpoints
were (a) the differences between the status of the ﬁrst biopsy
and that of the re-biopsy in the same patient population and (b)
the details of patients in which re-biopsy could not be carried
out. Safety assessments comprised the evaluation of re-biopsy-
associated complications. EGFR mutation assay was  performed by
the assay method at each institution.
2.5. Statistical analyses
The patient characteristics and comparisons between ﬁrst
biopsy/re-biopsy were summarized using descriptive statistics,
including number, mean, median, standard deviation, minimum
and maximum values for continuous variables, and frequency for
categorical variables. For the patients whose EGFR gene mutations
had been measured at re-biopsy, the proportion of patients with
positive T790M mutations was compared based on mutation types
at ﬁrst biopsy (Del19 only vs. L868R only) and treatment history at
re-biopsy (geﬁtinib, erlotinib, and afatinib). Treatment history was
classiﬁed into two categories for the between-treatment-history
comparison. The ﬁrst category is “in any line”, meaning that each
agent was prescribed in any line before re-biopsy, which allows
overlap of patients across multiple categories. The other category
is “single agent”, meaning that a single agent was prescribed before
re-biopsy, which limits patients to those treated with ﬁrst-line
therapy only. Fisher’s exact test was carried out for the compar-
ison between mutation types at ﬁrst biopsy, and “single agent”
treatment history at re-biopsy.
3. Results
3.1. Patients
A total of 401 patients were screened, of whom 6 were excluded
and 395 were evaluated (Fig. 1). The median age of the patients was
63 years (range, 27–84 years). The most frequent type of tumor his-
tology was  adenocarcinoma (380 patients, 96.2%). Regarding EGFR
mutation status, 219 (55.4%) patients had the Del19 mutation only,
while 149 (37.7%) patients had the L858R mutation only. Other
demographic and clinical characteristics of the patients are shown
in Table 1.
3.2. Results of re-biopsy
Rapid on-site evaluation and positron emission tomography
were performed in 34.7% (137/395) and 12.7% (50/395) of the
patients in the present study. The overall re-biopsy success rate
was 79.5% (314/395). The success rates by tumor site and sampling
method were also calculated (Supplementary Table 1). The suc-
cess rate of re-biopsy of the metastatic site (85.1% [103/121]) was
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igher than that of the re-biopsy of the other sites. The success rate
f percutaneous biopsy (88.5% [100/113]) was higher than that of
ransbronchial biopsy (73.9% [181/245]). At re-biopsy, 162 patients
41.0%) and 199 patients (50.4%) had an Eastern Cooperative Oncol-
gy Group (ECOG) performance status of 0 and 1, respectively. An
COG performance status of 2, 3, 4, and unknown was  reported in
7 (4.3%), 1 (0.3%), 1 (0.3%) and 15 (3.8%) patients, respectively. The
rimary tumor was the sampling site in 55.7% of patients, and trans-
ronchial tissue biopsy was the most common sampling method
62%). Entry to the clinical trial of 3rd generation TKI was the main
eason for re-biopsy in 281 (71.1%) patients. A total of 23 (5.8%)
atients presented re-biopsy-associated complications.
In terms of the safety of re-biopsy, the most common com-
lication was pneumothorax, which occurred in 2.5% of patients.
ampling method of these patients were all percutaneous needle
nder CT guidance. Further details of re-biopsy-associated compli-
ations are shown in Table 2.
.3. Differences between the ﬁrst biopsy and re-biopsy
Table 2 and Fig. 2 show the differences between the ﬁrst biopsy
nd re-biopsy. A higher proportion of re-biopsies vs ﬁrst biop-
ies were at the site of metastasis (30.6% vs 9.1%, respectively) or
egional lymph nodes (12.7% vs 7.1%, respectively). Surgical resec-
ion was the sampling method in more patients of re-biopsy (7.8%)
han ﬁrst biopsy (1.8%).w diagram.
3.4. Re-biopsy molecular proﬁle
A total of 296 (94.3%) patients underwent an EGFR mutation
assay, among whom 283 (90.1%) were found to have an EGFR muta-
tion. The detailed results of the EGFR mutation assay are shown in
Fig. 3. Other molecular tests performed were EML4 anaplastic lym-
phoma kinase (ALK), Kirsten rat sarcoma viral oncogene homolog
(KRAS), c-ros oncogene 1 (ROS1), and rearranged during transfec-
tion (RET) mutation assay. These were performed in 69 (22.0%), 45
(14.3%), 7 (2.2%), and 7 (2.2%) patients, respectively. Among patients
in whom molecular tests were performed, only two were found
to have the EML4–ALK mutation. There are 6 squamous cell car-
cinoma patients and 5 adenosquamous carcinoma patients at the
ﬁrst biopsy. Those mutation type and corresponding mutation type
at re-biopsy were summarized in Supplementary Table 2. For both
squamous cell carcinoma and adenosquamous carcinoma, T790M
was conﬁrmed at re-biopsy in one patient for each.
3.5. T790M induction by TKI/Therapy
Fig. 4 shows the development of T790M mutation stratiﬁed
by type of initial EGFR mutation and EGFR-TKI treatment. T790M
mutation was  induced in more patients with a Del19 mutation than
in those with an L858R mutation (55.6% vs 43.0%, respectively;
p = 0.05, Fisher’s exact test). No signiﬁcant difference was found
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Table 1
Patient demographic and clinical characteristics.
All patients
N = 395
Sex Male/female 154 (39.0%)/241 (61.0%)
Age,  years Median (range) 63 (27–84)
Smoking No/yes/unknown 247 (62.5%)/145 (36.7%)/3 (0.8%)
Past/current 116 (29.4%)/29 (7.3%)
Surgery No/yes 295 (74.7%)/100 (25.3%)
Type  of histology Adenocarcinoma 380 (96.2%)
Squamous cell carcinoma 6 (1.5%)
Adenosquamous carcinoma 5 (1.3%)
Other 4 (1.0%)
Large cell carcinoma 0 (0.0%)
EGFR  mutation
status
Del19 only/L858 R only 219 (55.4%)/149 (37.7%)
Others only 11 (2.8%)
L858R + others 7 (1.8%)
L858R + T790M 4 (1.0%)
Del19 + T790M 3 (0.8%)
Del19 + others 2 (0.5%)
ECOG PS
(At the time of re-biopsy)
0/1/2 162 (41.0%)/199 (50.4%)/17 (4.3%)
3/4/unknown 1 (0.3%)/1 (0.3%)/15 (3.8%)
TKI  treatment history before re-biopsy Geﬁtinib only/erlotinib only 212 (53.7%)/85 (21.5%)
Afatinib only/other mono only 7 (1.8%)/1 (0.3%)
Geﬁtinib + erlotinib 68 (17.2%)
Geﬁtinib + afatinib 8 (2.0%)
Geﬁtinib + other 1 (0.3%)
Erlotinib + afatinib 5 (1.3%)
More than 3 drugs 8 (2.0%)
Data are presented as n (%) except for age.
Abbreviations:  ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; PS, performance status; TKI, tyrosine kinase inhibitor.
Table  2
Comparison between the ﬁrst biopsy and re-biopsy.
Sampling method First biopsy Re-biopsy
Surgical resection 7 (1.8%) 31 (7.8%)
Tissue  biopsy Transbronchial biopsy, total 206 (52.2%) 245 (62.0%)
Forceps 185 (46.8%) 204 (51.6%)
Needle 19 (4.8%) 41 (10.4%)
Percutaneous method, total 30 (7.6%) 115 (29.1%)
Needle under CT guidance 24 (6.1%) 77 (19.5%)
Needle under ultrasonic guidance 4 (1.0%) 36 (9.1%)
Needle/unknown 2 (0.5%) 2 (0.5%)
Mediastinoscopy 0 (0.0%) 0 (0.0%)
Others 10 (2.5%) 4 (1.0%)
Cytology Transbronchial biopsy, total 156 (39.5%) 66 (16.7%)
Scratch 123a (31.1%) 40a (10.1%)
Needle 13a (3.3%) 12a (3.0%)
Lavage 81a (20.5%) 40a (10.1%)
Percutaneous method, total 31 (7.8%) 14 (3.5%)
Needle under CT guidance 9 (2.3%) 8 (2.0%)
Needle under ultrasonic guidance 18 (4.6%) 4 (1.0%)
Needle/unknown 4 (1.0%) 2 (0.5%)
Others 20 (5.1%) 3 (0.8%)
Adverse events
Total 5 (1.3%) 23 (5.8%)
Hemoptysis 0 (0.0%) 1 (0.3%)
Pneumothorax 1 10 (2.5%)
Pneumonitis 1 1 (0.3%)
Empyema thoracic 0 (0.0%) 0 (0.0%)
Ecchymoma 1 1 (0.3%)
Aeroembolism 0 (0.0%) 0 (0.0%)
Othersb 2 11 (2.8%)
Data are presented as n (%).
Abbreviation: CT, computed tomography.
a The scratch, needle, or lavage method may  have been used more than once.
b In the re-biopsy group, the other adverse events were: anterior chest pain; postoperative would infection; right chest pain; infection (fever); diarrhea, incision infection,
and  fever (in one patient); fever and pain (in one patient); pneumogastric nerve disorder; subcutaneous hemorrhage; bleeding after transbronchial biopsy; small hemorrhage
after  biopsy; and hemorrhage at bronchoscopy.
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Fig. 2. Comparison between the initial biopsy and re-biopsy.
a  and b: Sampling site (n = 395). Metastasis (n = 36 in Fig. 2a, n = 121 in Fig. 2b) includes distant metastasis, lung metastasis, and distant lymph node metastasis.
c  and d: Sampling site from metastasis.
Abbreviation: pts, patients
Fig. 3. Results of the EGFR mutation assay after re-biopsy.
The number of patients with re-biopsy success was  314. EGFR mutation assay was conducted in 296 patients. The reasons not conducting EGFR mutation assay were other
target  mutation assays such as PD-L1 assay in 2 patients, PIK3CA assay in one patient, EML4-ALK assay was in 2 patients, transformation to small cell lung cancer in 12
patients.  For the remaining 4 patients, the reason was  unknown.
Abbreviation: EGFR, epidermal growth factor receptor; pts, patients
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 = 0.05 (Fisher’s exact test) for Del19 mutation vs L858R mutation.
bbreviation: EGFR, epidermal growth factor receptor
n the number of T790 mutations between patients treated with
eﬁtinib only and erlotinib only.
. Discussion
In this multicenter, observational, retrospective study, the re-
iopsy success rate was approximately 80%. The success rate
n the previously reported studies varies between 73% to 95%
11,12,14–19] and our result is within the range. Although there
re several reports of re-biopsy, there are few studies that focus on
easibility of re-biopsy and re-biopsy status. To our knowledge, in
apan, this is the ﬁrst report that describes re-biopsy status includ-
ng success rate in a large number of patients.
A possible reason for the high success rate in the present study
s that many of the institutes included have more experience
onducting re-biopsies owing to participation in the clinical trial
f a third-generation TKI. Among all re-biopsy samples, 281/395
71.1%) were taken for a third-generation TKI clinical trial. Further-
ore, several of these institutes used rapid on-site evaluation and
ositron emission tomography.
The proportion of patients with EGFR mutation at re-biopsy has
aried between studies. Approximately 50% of the patients in this
tudy were found to have T790M mutations. There are several
eports of tumor specimens at the time of acquired resistance to
GFR-TKI treatment. Oxnard et al. reported a 60% frequency of EGFR
790M mutations and other rare second site mutations at re-biopsy
8], and Yu et al. reported a 62% frequency of T790M mutations
7]. Small cell histology transformation occurred in 2.2% of patients
n this study. Yu et al. reported a 1% frequency of small cell histo-
ogic transformation at the time of acquired resistance to EGFR-TKI,
hile Oxnard et al. reported 6% [7,8]. It seems that other mutation
ests such as those for KRAS and ALK are not commonly performed.
Regarding the sampling procedure, the proportion of cytol-
gy sample in this study was slightly higher than that reported
y Chouaid et al., but lower than that reported by Arcila et al.
12,14]. We found that the differences between the ﬁrst biopsy andGFR-TKI treatment.
re-biopsy sites showed an increase of metastasis at re-biopsy, espe-
cially in the lung (pulmonary metastasis) and liver. Compared with
the sampling method at the ﬁrst biopsy, at re-biopsy, the rate of
surgical resection increased from 1.8% to 7.8%, and percutaneous
tissue biopsy increased from 7.6% to 29.1%. This ﬁnding illustrates
the difﬁculty of performing re-biopsy. A larger volume of tissue
resection may  lead to a higher re-biopsy success rate.
Comparing our study to the studies from western countries, it
seemed to be a different tendency in terms of sampling method of
re-biopsy. Most of re-biopsy method in Japan is a transbronchial
tissue biopsy [10,11], while surgical biopsy and guided biopsy are
more used in western countries [12,14,15,18].
In our study, the complication rate at re-biopsy was 5.8%, which
was higher than that at the ﬁrst biopsy (1.3%). The most frequent
complication was  pneumothorax (2.5%). The complication at re-
biopsy was  reported one case (1%) of pneumothorax, and 2 cases
(2%) of hemoptysis [12], also postprocedural complications were
reported 13 (14%) of 94 patients (6% of pneumothorax, 7% of intra-
pulmonary hemorrhage) [18]. Considering the previous reports and
our result, pneumothorax and hemorrhage are the complications
that physician needs to understand how to manage those. Jekunen
(2015) reported that adequate evaluation of risks for complications
should be performed including anatomic and technical aspects of
accessing tumor before performing re-biopsy [20].
We also investigated which pattern had increased T790M muta-
tion by type of initial EGFR mutation and previous treatment
type. In our study, the T790M mutation was  more frequently
induced in patients with a Del19 mutation (55.6%) than in those
with an L858R mutation (43.0%) (p = 0.05). T790M induction was
observed in 52.8%, 44.6%, and 20.0% of patients after only geﬁtinib,
erlotinib, or afatinib treatment. Although the number of afatinib
treatment patients was  small, there seemed to be a tendency that
the ﬁrst-generation TKI induced more T790M mutations than the
second-generation TKI. Further investigation of the resistant mech-
anism of the second-generation TKI is warranted to consider the
best treatment sequence.
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Re-biopsy after disease progression will become necessary
or all institutions as a T790M-targeted third-generation TKI,
simertinib [AZD9291], has just launched in Japan. The present
tudy provides important information on re-biopsy that may  help
mprove the selection of patients who may  beneﬁt from third-
eneration TKIs.
The present study has some limitations, including those inher-
nt to the retrospective study design and the possibility of bias. As
entioned previously, our ﬁndings cannot be generalized to the
eneral Japanese population because only specialized study insti-
utes were included. A further potential weakness is the absence
f information on patients who did not undergo a re-biopsy
espite EGFR-TKI resistance, and this warrants further investi-
ation. Strictly speaking, our data cannot be used to determine
he percentage of patients with progressive disease in which re-
iopsy can be conducted. However, the study does provide valuable
nformation that may  assist in selecting patients after EGFR-TKI
reatment who may  be suitable for re-biopsy. The fact that our study
ncluded a relatively large patient sample size represents strength
f the study.
. Conclusions
Success rate for re-biopsy in this study was approximately 80%
nd the rate is almost similar to the studies previously reported. Our
tudy sheds light on the re-biopsy status after disease progression
n patients with advanced or metastatic NSCLC. This information
s important to improve the selection of patients who  may  beneﬁt
rom third-generation TKIs.
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